olodaterol + fluconazole

Olodaterol + fluconazole is a drug combination primarily utilized in clinical pharmacology studies to evaluate drug-drug interactions. Olodaterol is a highly selective, long-acting beta2-adrenergic agonist (LABA) developed by Boehringer Ingelheim for the treatment of chronic obstructive pulmonary disease (COPD). Fluconazole is a triazole antifungal agent that acts as a potent inhibitor of the cytochrome P450 enzyme CYP2C9 and a moderate inhibitor of CYP2C19. Because olodaterol is partially metabolized by these enzymes, the combination is studied to determine if fluconazole-mediated inhibition increases the systemic exposure or alters the safety profile of olodaterol. There is no commercially available fixed-dose combination of these two agents.

Other names

olodaterol and fluconazole